Subscribe to RSS
Download PDF
DOI: 10.1160/TH08-12-0813
Fibrinogen gamma gene 3’-end polymorphisms and risk of venous thromboembolism in the African-American and Caucasian population
Financial support: This study was financially supported by grant 912–02–036 from the Netherlands Organization for Scientific Research (NWO). The GATE study was supported by a grant from the CDC through the Associations of Schools of Public Health/CDC Cooperative Agreement mechanism.
Publication History
Received:
13 December 2008
Accepted after minor revision:
12 February 2009
Publication Date:
24 November 2017 (online)
Summary
Genetic determinants of venous thromboembolism (VTE) in the African-American population are poorly characterised. It was recently shown that fibrinogen gamma gene (FGG) polymorphisms 10034C>T and 9340T>C influence VTE risk in the Caucasian population. In the African-American population these polymorphisms are common, with allele frequencies above 25%. Here we evaluated whether these and other FGG 3’-end polymorphisms were associated with VTE risk in the African-American population and aimed to replicate the association in the Caucasian population. We examined 557 Caucasian patients and 678 Caucasian controls, and 537 African-American patients and 586 African-American controls from the ‘Genetic Attributes and Thrombosis Epidemiology’ (GATE) study. In the African-American population, 10034C>T and 9340T>C marginally influenced VTE-risk, with a 20% increase in risk for 10034TT carriers and a 20% reduction in risk for 9340CC carriers. In the Caucasian population, 10034TT was associated with a 1.7-fold increase in risk, which increased to 2.1-fold for idiopathic VTE patients. 9340CC significantly reduced VTE risk approximately two-fold. In conclusion, both FGG polymorphisms 10034C>T and 9340T>C influence VTE-risk, with the strongest effects observed in the Caucasian population, confirming previous data on these polymorphisms in this population.
-
References
- 1 Silverstein MD, Heit JA, Mohr DN. et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-593.
- 2 White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 1998; 128: 737-740.
- 3 Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-1173.
- 4 Bertina RM, Koeleman BP, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
- 5 Poort SR, Rosendaal FR, Reitsma PH. et al. A common genetic variation in the 3‘-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
- 6 Hooper WC, Dilley A, Ribeiro MJ. et al. A racial difference in the prevalence of the Arg506-->Gln mutation. Thromb Res 1996; 81: 577-581.
- 7 Dilley A, Austin H, Hooper WC. et al. Prevalence of the prothrombin 20210 G-to-A variant in blacks: infants, patients with venous thrombosis, patients with myocardial infarction, and control subjects. J Lab Clin Med 1998; 132: 452-455.
- 8 Rees DC, Chapman NH, Webster MT. et al. Born to clot: the European burden. Br J Haematol 1999; 105: 564-566.
- 9 White RH, Zhou H, Murin S. et al. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost 2005; 93: 298-305.
- 10 Dowling NF, Austin H, Dilley A. et al. The epidemiology of venous thromboembolism in Caucasians and African-Americans: the GATE Study. J Thromb Haemost 2003; 1: 80-87.
- 11 Uitte de Willige S, de Visser MCH, Houwing-Duistermaat JJ. et al. Genetic variation in the fibrinogen gamma gene increases the risk of deep venous thrombosis by reducing plasma fibrinogen {gamma}’ levels. Blood 2005; 106: 4176-4183.
- 12 Grunbacher G, Weger W, Marx-Neuhold E. et al. The fibrinogen gamma (FGG) 10034C>T polymorphism is associated with venous thrombosis. Thromb Res 2007; 121: 33-36.
- 13 Uitte de Willige S, Doggen CJM, de Visser MCH. et al. Haplotypes of the fibrinogen gamma gene do not affect the risk of myocardial infarction. J Thromb Haemost 2006; 4: 474-476.
- 14 Koch W, Hoppmann P, Biele J. et al. Fibrinogen genes and myocardial infarction – A haplotype analysis. Arterioscler Thromb Vasc Biol 2008; 28: 758-763.
- 15 Cheung EY, Uitte de Willige S, Vos HL. et al. Fibrinogen gamma’ in ischemic stroke: a case-control study. Stroke 2008; 39: 1033-1035.
- 16 Uitte de Willige S, Rietveld IM, de Visser MC. et al. Polymorphism 10034C > T is located in a region regulating polyadenylation of FGG transcripts and influences the fibrinogen gamma‘/gammaA mRNA ratio. J Thromb Haemost 2007; 5: 1243-1249.
- 17 Nickerson D. SeattleSNPs. NHLBI Program for Genomic Applications. UW-FHCRC; Seattle, WA.: http://pga.gs.washington.edu 2003
- 18 The International HapMap Project. Nature 2003; 426: 789-796.
- 19 Austin H, Key NS, Benson JM. et al. Sickle cell trait and the risk of venous thromboembolism among blacks. Blood 2007; 110: 908-912.
- 20 Livak KJ. Allelic discrimination using fluorogenic probes and the 5’ nuclease assay. Genet Anal 1999; 14: 143-149.
- 21 Barrett JC, Fry B, Maller J. et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
- 22 Dilley A, Austin H, Hooper WC. et al. Relation of three genetic traits to venous thrombosis in an African-American population. Am J Epidemiol 1998; 147: 30-35.
- 23 Hooper WC, Lally C, Austin H. et al. The relationship between polymorphisms in the endothelial cell nitric oxide synthase gene and the platelet GPIIIa gene with myocardial infarction and venous thromboembolism in African Americans. Chest 1999; 116: 880-886.
- 24 Austin H, Hooper WC, Lally C. et al. Venous thrombosis in relation to fibrinogen and factor VII genes among African-Americans. J Clin Epidemiol 2000; 53: 997-1001.
- 25 Hooper WC, Lally C, Austin H. et al. The role of the t-PA I/D and PAI-1 4G/5G polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism. Thromb Res 2000; 99: 223-230.
- 26 Hooper WC, Dowling NF, Wenger NK. et al. Relationship of venous thromboembolism and myocardial infarction with the renin-angiotensin system in African-Americans. Am J Hematol 2002; 70: 1-8.
- 27 Patel RK, Ford E, Thumpston J. et al. Risk factors for venous thrombosis in the black population. Thromb Haemost 2003; 90: 835-838.
- 28 Herrmann FH, Salazar-Sanchez L, Schuster G. et al. Prevalence of eight molecular markers associated with thrombotic diseases in six Amerindian tribes and two African groups of Costa Rica. Am J Hum Biol 2004; 16: 82-86.
- 29 Carter AM, Catto AJ, Kohler HP. et al. Alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism. Blood 2000; 96: 1177-1179.
- 30 Falls LA, Farrell DH. Resistance of gammaA/ gamma’ fibrin clots to fibrinolysis. J Biol Chem 1997; 272: 14251-14256.
- 31 Cooper AV, Standeven KF, Ariëns RA. Fibrinogen gamma-chain splice variant {gamma}’ alters fibrin formation and structure. Blood 2003; 102: 535-540.
- 32 Standeven KF, Grant PJ, Carter AM. et al. Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation 2003; 107: 2326-2330.
- 33 Sinha M, Larkin EK, Elston RC. et al. Self-reported race and genetic admixture. N Engl J Med 2006; 354: 421-422.
- 34 Mosesson MW, Hernandez I, Raife TJ. et al. Plasma fibrinogen gamma prime chain content in the thrombotic microangiopathy syndrome. J Thromb Haemost 2006; 5: 62-69.